CytoSorbents CEO named finalist for E&Y award

Dr. Phillip Chan, CEO of CytoSorbents (OTCBB: CTSO.OB) has been named a finalist in the Ernst & Young Entrepreneur of the Year 2012 program in the New Jersey region. The award recognizes outstanding entrepreneurs who have demonstrated excellence and extraordinary success in areas such as innovation, financial performance and personal commitment to their businesses and [...]

Thallion and LFB post positive Phase 2 E. coli trial results

Thallion Pharmaceuticals (TSX:TLN) and LFB Biotechnologies reported positive top-line results from the Phase 2 SHIGATEC trial evaluating Thallion’s Shigamabs drug candidate as a treatment for Shiga toxin-producing E. coli (STEC) infection at the 8th International Symposium on Shiga Toxin (Verocytotoxin)-Producing Escherichia coli Infections (VTEC 2012) in Amsterdam. “Based on core Phase 2 data, the study has met [...]

Roth upgrades Keryx to buy

Roth Capital Partners has upgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “buy” from “neutral” and raised its 12-month price target to $7 from $4, saying that “with the perifosine dust settled, the fundamentals of the Zerenex story are intact.” The stock closed at $1.45 on Wednesday. Zerenex is in development for the treatment of hyperphosphatemia in end-stage [...]

Hamilton Thorne gets CE mark for LYKOS laser system

Hamilton Thorne (TSX-V:HTL) has received a CE mark for its new LYKOS-assisted clinical reproductive laser system, providing conformity to European Medical Device Directive 93/42/EEC, and allowing for sales and marketing of products in the European Economic Area. Hamilton Thorne’s best-in-class LYKOS laser system is used for intricate clinical procedures such as laser-assisted hatching, trophectoderm biopsy [...]

pSivida’s ILUVIEN cleared in UK for DME

The Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA) has granted marketing authorization for pSivida’s (NASDAQ:PSDV; ASX:PVA) ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. Additional marketing authorizations are expected in the coming months and marketing partner Alimera Sciences continues to [...]

Cynpasus CEO interview by CEOCFO Magazine

In a wide ranging interview with CEOCFO Magazine, Cynapsus Therapeutics (TSX-V:CTH) CEO Anthony Giovinazzo discusses the current state of the company and the status of its sublingual thin film strip, APL-130277, as a treatment for Parkinson’s disease. Mr. Giovinazzo also delves into the market potential for APL-130277, marketing surveys with neurologists worldwide, the cost of [...]

Microbix welcomes European revocation of Inguran sperm patent

Microbix Biosystems (TSX:MBX) has welcomed a decision by the European Patent Office revoking a patent on frozen-sperm/XY held by Inguran LLC, doing business as Sexing Technologies LLC and XY LLC. The patent relates to the use of cryopreservation technology for sperm cells sorted into sex-selected populations. Microbix participated in the opposition proceedings through direct submission [...]

Novadaq Q1 revenue beats consensus

Revenue for Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) jumped 103% to $4.8 million in the first quarter this year, beating analysts’ consensus of $4.6 million, on increased sales of systems and procedure kits across both of its commercial SPY Imaging businesses: SPY Elite and FIREFLY. The combined installed base of SPY technology in the U.S. now exceeds [...]

Cipher posts Q1 profit on 168% revenue gain

Cipher Pharmaceuticals (TSX:DND; OTCBB:CPHMF) achieved a profit of $125,000 in the first quarter this year, compared with a year earlier loss of $1.1 million, as revenue rose 168% to $1.8 million. “Revenue grew strongly in the first quarter based on Lipofen’s performance and early contributions from ConZip, which was recently launched in the U.S.,” CEO [...]

Cynapsus nominates Molinoff and Picone as directors

Cynapsus Therapeutics (TSX-V:CTH) has nominated Dr. Perry Molinoff, former Vice Provost of the University of Pennsylvania, and Dr. Thomas Picone, a seasoned senior pharma executive, to join the board at the annual meeting on May 30, 2012. Cynapsus president and CEO Anthony Giovinazzo will also join the board, replacing David Hill, who is stepping down. [...]

« Previous Page — Next Page »